Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Anavex Life Sciences Corp. AVXL
$8.99
-$0.2 (-2.23%)
На 18:00, 12 мая 2023
+22.36%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
786005226.00000000
-
week52high
15.24
-
week52low
7.13
-
Revenue
0
-
P/E TTM
-13
-
Beta
0.75190300
-
EPS
-0.67000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Berenberg | Buy | 23 июн 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 02 февр 2022 г. |
| BTIG | Buy | 23 сент 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 28 июн 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 15 июн 2021 г. |
| Cantor Fitzgerald | Neutral | Overweight | 06 дек 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Velden Claus Vander | A | 50000 | 50000 | 27 июн 2022 г. |
| Thomas Steffen | A | 50000 | 50000 | 27 июн 2022 г. |
| Donhauser Peter D.O. | A | 50000 | 50000 | 27 июн 2022 г. |
| Skarpelos Athanasios | A | 50000 | 50000 | 27 июн 2022 г. |
| Ma Jiong | A | 50000 | 50000 | 27 июн 2022 г. |
| Skarpelos Athanasios | A | 0 | 50000 | 25 мая 2022 г. |
| Skarpelos Athanasios | D | 1306458 | 50000 | 25 мая 2022 г. |
| Skarpelos Athanasios | A | 1356458 | 50000 | 25 мая 2022 г. |
| Ma Jiong | A | 25000 | 25000 | 02 авг 2021 г. |
| Boenisch Sandra | A | 40000 | 40000 | 02 авг 2021 г. |
Новостная лента
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
GlobeNewsWire
02 мая 2023 г. в 07:30
Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
GlobeNewsWire
25 апр 2023 г. в 07:30
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ being held May 2nd, 2023 at 9:30am ET at NASDAQ World Headquarters New York City.
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
GlobeNewsWire
10 апр 2023 г. в 07:00
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other Central Nervous System (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the 22nd Annual Needham Virtual Healthcare Conference 2023 on Monday, April 17, 2023, at 8:00 AM ET.
Buy Anavex For Its Likely Positive Alzheimer's Disease Data
Seeking Alpha
16 мар 2023 г. в 04:06
The ANAVEX2-73-AD-004 trial was mostly positive. A reputable journal article on the missing data would allay fears of a 'spin'.
Anavex: Many Questions Answered, A Few Still Left, But Things Are Progressing Well
Seeking Alpha
08 мар 2023 г. в 08:50
Anavex seems to have effectively handled the Rett syndrome endpoint issues. A future publication should also throw more light on the AD data.